Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2020
BMS appeals final appraisal document for nivolumab for non-small cell lung cancer
30 October 2020 - The appeal will be heard on 1 December 2020. ...
Posted by Michael Wonder on 30 Oct 2020
NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease
30 October 2020 - All eligibility criteria must be met for liraglutide to be offered. ...
Posted by Michael Wonder on 30 Oct 2020
ICR welcomes NICE’s decision to reassess abiraterone acetate as first-line treatment for advanced prostate cancer
29 October 2020 - The Institute of Cancer Research, London, has welcomed the announcement by NICE that it will reconsider ...
Posted by Michael Wonder on 30 Oct 2020
The NICE MEDLINE and Embase (Ovid) health apps search filters: development of validated filters to retrieve evidence about health apps
27 October 2020 - Health apps are software programs that are designed to prevent, diagnose, monitor, or manage conditions. ...
Posted by Michael Wonder on 29 Oct 2020
NICE announces start of review of nusinersen Managed Access Agreement
29 October 2020 - NICE has today announced that it has begun the process to review data collected as part of ...
Posted by Michael Wonder on 27 Oct 2020
NICE publishes appraisal consultation document for avapritinib
27 October 2020 - Avapritinib is used to treat patients with an unresectable or metastatic gastro-intestinal stromal tumour. ...
Posted by Michael Wonder on 26 Oct 2020
ICR urges change as NICE rejects Keytruda plus chemotherapy
23 October 2020 - The Institute for Cancer Research has called for change in the way immunotherapy drugs are researched ...
Posted by Michael Wonder on 26 Oct 2020
NICE recommends Bayer’s Nubeqa (darolutamide), a new treatment option for non-metastatic castration-resistant prostate cancer
23 October 2020 - Positive recommendation based on Phase 3 ARAMIS trial data in which darolutamide plus androgen deprivation therapy showed ...
Posted by Michael Wonder on 23 Oct 2020
Efficiency ratio and rocketing drug prices: old concerns and new possibilities
23 October 2020 - One of the most significant phenomena in the recent years concerning the pharmaceutical industry and, at ...
Posted by Michael Wonder on 21 Oct 2020
NICE in favour of another highly specialised technology
21 October 2020 - Familial chylomicronaemia syndrome is a rare and potentially life-threatening condition that has a significant effect on the ...
Posted by Michael Wonder on 21 Oct 2020
NICE recommended use of Opdivo for another indication
20 October 2020 - This marks the tenth NICE recommendation for nivolumab. ...
Posted by Michael Wonder on 18 Oct 2020
Community engagement in health technology assessment and beyond: from guests in the process to hosts
15 October 2020 - In health technology assessment, clinical and economic evidence are assessed in the regulatory and reimbursement environments, with ...
Posted by Michael Wonder on 16 Oct 2020
NICE gears up to support world evidence-based health care day
16 October 2020 - Inaugural World Evidence-based Health care Day takes place on Tuesday 20 October 2020. ...
Posted by Michael Wonder on 15 Oct 2020
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
15 October 2020 - NICE has today issued draft guidance which now recommends siponimod (Mayzent; Novartis) for treating secondary progressive multiple ...
Posted by Michael Wonder on 15 Oct 2020
NICE recommends Novartis’ Mayzent on the heels of SMC approval
15 October 2020 - NICE has recommended Novartis’ Mayzent for use by NHS England, only a few days after the ...